Lung Cancer Clinical Trials in Los Angeles

Showing 501-509 of 509 trials

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00964132

The purpose of this study is to determine whether NRX 194204 is effective in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC).

Non-small Cell Lung Cancer

NuRx Pharmaceuticals, Inc.48 participantsStarted Mar 2009

Fountain Valley, California, United States • La Jolla, California, United States • Los Angeles, California, United States +3 more locations

COMPLETEDPhase 2< 1 mile

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

NCT00116610

This is a Phase II research study that is designed for patients who have small cell lung cancer (SCLC) that is no longer responding to treatment. Patients will receive picoplatin, a new platinum-based agent that is currently under investigation, in 21-day cycles.

Small Cell Lung Cancer

Poniard Pharmaceuticals75 participantsStarted Jun 2005

Hot Springs, Arkansas, United States • Los Angeles, California, United States • Palm Springs, California, United States +52 more locations

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Lung Cancer Trials in Other Cities

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Other Conditions in Los Angeles